Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study
source: American Society of Hematology
authors: Ersi Voskaridou, Stephan Lobitz, Uwe Kordes, Regine Grosse, Valentine Brousse, Malika Benkerrou, Mariane De Montalembert, Jean-Antoine Ribeil, Frederic Galacterossummary/abstract:
ESCORT-HU (European Sickle Cell Disease (SCD) COhoRT – HydroxyUrea) is a multicenter prospective non interventional study implemented in Europe, following the European Medical Agency’s request to collect more information focused on long-term safety profile of hydroxycarbamide (HU) in SCD patients treated with HU. Primary endpoint of the study is to determine the frequency of adverse events (AEs) under HU treatment Secondary endpoints include the efficacy of HU in labeled indications (prevention of vaso-occlusive complications and of acute thoracic syndrome), frequency of hospitalizations due to SCD events and frequency of blood transfusions. Data collection on the reason for HU initiation permitted to identify in-label (in the therapeutic indication of the European marketing authorization, group 1, G1) and off-label (other therapeutic indication, group 2, G2) prescriptions of HU. Frequency of AEs (including not related to SCD and infections) was compared between adults and children, both in G1 and G2, with focus on the following subclasses: blood and lymphatic system disorders, fever, gastrointestinal disorders, infection, nervous system disorders, skin and subcutaneous tissue disorders and others.organization: Laiko General Hospital, Athens; Charité-Universitätsmedizin, Berlin; Universitätsklinikum Hamburg-Eppendorf; University Medical Center Hamburg-Eppendorf; Hôpital Universitaire Necker-Enfants Malades, Paris; Laboratory of Excellence, GR-ex, Paris; Hopital Robert Debré, APHP, Paris; Centre de la Drépanocytose, Hôpital Henri Mondor, Creteil
Hydroxyurea for children with sickle cell anemia in Sub-Saharan AfricaBackground: Hydroxyurea is an effective...
Siklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home programMedunik USA announced today that...
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
Guideline Information for PatientsLiving with chronic pain can be devastat...
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
Blood Transfusions: What You Need to Know and Do (Part 3: IRON OVERLOAD)https://www.youtube.com/watch?v=aXURPZav...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.